TScan Therapeutics, Inc. (TCRX) Institutional Ownership

Ownership Summary

TScan Therapeutics, Inc. (NASDAQ:TCRX) showed up in the 13F filings of 60 institutional investors as of December 2025.

• They owned 23.6% of outstanding stock in December 2025, down from 27.1% the prior quarter.
• They increased total shares held in TCRX by 0.01% quarter over quarter, and investors in TScan Therapeutics decreased 34.07% from a year ago.
• During the quarter, 27 of these 60 funds increased positions in TCRX, 19 reduced exposure, and 14 held steady.
• The aggregate institutional position in TScan Therapeutics amounted to 30.69Mn shares as of December 2025, up by 4.57K shares quarter on quarter, and down 11.35Mn shares year over year.
• As of December 31, 2025, Lynx1 Capital Management LP held the largest stake in TScan Therapeutics with 8.02Mn shares, accounting for 6.18% of total shares outstanding.
• Leading buyers of TScan Therapeutics shares for the quarter ending December 2025 were Aberdeen Group plc (430.42K), RENAISSANCE TECHNOLOGIES LLC (311.15K), JANE STREET GROUP, LLC (306.97K), MARSHALL WACE, LLP (292.61K), TWO SIGMA INVESTMENTS, LP (231.78K).
• Top sellers of TCRX stock for the quarter ending December 2025 included Morgan Stanley (621.71K), TANG CAPITAL MANAGEMENT LLC (553.87K), BlackRock, Inc. (534.07K), Jpmorgan Chase & Co (442.15K), Bank Of America Corp /De/ (407.35K).
• TScan Therapeutics's 10 largest shareholders as of December 2025 include Lynx1 Capital Management LP (8.02Mn), BVF INC/IL (5.23Mn), BAKER BROS. ADVISORS LP (2.78Mn), VANGUARD GROUP INC (2.48Mn), BlackRock, Inc. (1.85Mn), Aberdeen Group plc (1.79Mn), Deer Management Co. LLC (1.25Mn), RENAISSANCE TECHNOLOGIES LLC (1.14Mn), TWO SIGMA INVESTMENTS, LP (651.18K), DC Funds, LP (630.0K) per Business Quant data.